Second dose of experimental drug offers hope for rare blood conditions
NCT ID NCT07039422
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 24 times
Summary
This study is for adults with two rare blood disorders—immune thrombocytopenia (ITP) and warm-antibody autoimmune hemolytic anemia (wAIHA)—who have already benefited from the drug ianalumab in a previous trial. Researchers want to see if a second course of ianalumab can control the disease again after it returns. About 60 participants will receive the drug and be monitored for response and safety over 12 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY IMMUNE THROMBOCYTOPENIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Locations
-
Novartis Investigative Site
RECRUITINGRoeselare, West-Vlaanderen, 8800, Belgium
-
Novartis Investigative Site
RECRUITINGGuangzhou, Guangdong, 510515, China
-
Novartis Investigative Site
RECRUITINGTianjin, 300020, China
-
Novartis Investigative Site
RECRUITINGOstrava, Poruba, 708 52, Czechia
-
Novartis Investigative Site
RECRUITINGJena, Thuringia, 07740, Germany
-
Novartis Investigative Site
RECRUITINGDebrecen, Hajdu Bihar Megye, 4032, Hungary
-
Novartis Investigative Site
RECRUITINGFlorence, FI, 50134, Italy
-
Novartis Investigative Site
RECRUITINGTrieste, TS, 34129, Italy
-
Novartis Investigative Site
RECRUITINGVicenza, VI, 36100, Italy
-
Novartis Investigative Site
RECRUITINGGeorge Town, 10050, Malaysia
-
Novartis Investigative Site
RECRUITINGSingapore, 119074, Singapore
-
Novartis Investigative Site
RECRUITINGMadrid, 28009, Spain
-
Novartis Investigative Site
RECRUITINGSamsun, Atakum, 55200, Turkey (Türkiye)
-
Novartis Investigative Site
RECRUITINGLondon, W12 0HS, United Kingdom
Conditions
Explore the condition pages connected to this study.